Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table of Content (TOC)<br />
Chapter 1: Introduction<br />
Chapter 2: Executive Summary<br />
Chapter 3: <strong>Market</strong> Overview<br />
Chapter 4: <strong>Market</strong> Beyond: What To Expect By 2025<br />
Chapter 5: Global <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Market</strong> By Drug Types<br />
Chapter 6: Global <strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> <strong>Market</strong> (Pipeline Drug Analysis)<strong>by</strong><br />
Geography, 2013-<strong>2020</strong><br />
Chapter 8. Company Profiles